163 related articles for article (PubMed ID: 38597118)
21. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
22. Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007-2015.
Morrison VA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Galaznik A
J Geriatr Oncol; 2020 Jan; 11(1):41-54. PubMed ID: 31416716
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
24. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Tsutsué S; Tobinai K; Yi J; Crawford B
PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
[TBL] [Abstract][Full Text] [Related]
25. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract][Full Text] [Related]
26. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
27. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
[TBL] [Abstract][Full Text] [Related]
28. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
Masir N; Akhter A; Roshan TM; Florence CS; Abdul-Rahman F; Tumian NR; Kean-Chang P; Elyamany G; Shabani-Rad MT; Mansoor A
J Clin Pathol; 2019 Sep; 72(9):630-635. PubMed ID: 31189540
[TBL] [Abstract][Full Text] [Related]
30. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic developments and advances in B-cell lymphoma].
Miyazaki K
Rinsho Ketsueki; 2022; 63(6):619-625. PubMed ID: 35831197
[TBL] [Abstract][Full Text] [Related]
32. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
[TBL] [Abstract][Full Text] [Related]
33. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
34. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
[TBL] [Abstract][Full Text] [Related]
35. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma.
Harris W; Bataillard EJ; Choi Y; El-Galaly TC; Cuchelkar V; Henneges C; Kwan A; Schneider DJ; Paulson JN; Nielsen TG
JCO Clin Cancer Inform; 2022 Jan; 6():e2100121. PubMed ID: 35044836
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
37. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
38. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Major A; Smith SM
Clin Adv Hematol Oncol; 2021 Nov; 19(11):698-709. PubMed ID: 34807015
[TBL] [Abstract][Full Text] [Related]
39. Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Burke JM; Masaquel A; Wang R; Hossain F; Li J; Zhou SQ; Ng CD; Matasar M
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e393-e404. PubMed ID: 37704514
[TBL] [Abstract][Full Text] [Related]
40. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.
Ip A; Mutebi A; Wang T; Jun M; Kalsekar A; Navarro FR; Wang A; Kamalakar R; Sacchi M; Elliott B
Adv Ther; 2024 Mar; 41(3):1226-1244. PubMed ID: 38302846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
